The Presence of Genetic Mutations at Key Loci Predicts Progression to Esophageal Adenocarcinoma in Barrett’s Esophagus

Eluri, Swathi; Brugge, William R.; Daglilar, Ebubekir; Jackson, Sara; Styn, Mindi A.; Callenberg, Keith M.; Welch, Derek C.; Barr, Todd M.; Duits, Lucas C.; Bergman, Jacques; Shaheen, Nicholas J.

doi:10.1038/ajg.2015.152

Cited by 33 publications

(40 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The extent of genomic instability, measured as the mutational load in a biopsy of BE, can predict the risk of progression of BE to EAC in patients who otherwise would have been deemed low risk on the basis of histological findings alone. Mutational load summarizes the presence and clonality of loss of heterozygosity (LOH) mutations and the emergence of new alleles, manifested as microsatellite instability (MSI) mutations, in ten genomic loci around tumor suppressor genes associated with EAC (28,29).…”

Section: Barrett's Esophagus (Be)mentioning

confidence: 99%

Overview of esophageal cancer

Abbas¹,

Krasna²

2017

Ann. Cardiothorac. Surg.

176

168

View full text Add to dashboard Cite

Esophageal cancer is a male-dominant aggressive malignancy and a leading cause of cancer-related mortality worldwide. Squamous cell carcinoma and adenocarcinoma are the two predominant histological subtypes with varying geographical and racial distribution. Globally, squamous cell carcinoma remains the most common histological type. In Western countries, however, adenocarcinoma has become the leading histological subtype, corresponding to a rise in the incidence of obesity, gastro-esophageal reflux disease and Barrett's esophagus. The risk of esophageal adenocarcinoma conferred by Barrett's esophagus depends on factors such as genomic instability, race and gender of the patient. Treatment requires a multidisciplinary team approach and optimal therapy is still debated. Endoscopic therapies, including radiofrequency ablation, endoscopic mucosal resection and endoscopic sub mucosal dissection, have become the standard treatment modality for Barrett's esophagus and early carcinoma. Multimodal treatment, which includes chemotherapy, radiation therapy followed by surgical resection or without surgical resection, in varying orders remains the main mode of treatment for most patients. Minimally invasive surgical approaches have become the standard for esophagectomy and the current literature has demonstrated similar oncological outcomes with reduced morbidity. Recently, there has been a modest improvement in the overall survival of patients with esophageal cancer.

show abstract

Section: Barrett's Esophagus (Be)mentioning

confidence: 99%

Overview of esophageal cancer

Abbas¹,

Krasna²

2017

Ann. Cardiothorac. Surg.

176

168

View full text Add to dashboard Cite

show abstract

“…Biomarker panels have been used in recent years to determine the risk of dysplasia and neoplasia in the setting of BE . Such methods include examining gene methylation arrays and mutational load . Recently, a systematic review suggested a possible role for p16 hypermethylation as an individual epigenetic biomarker in predicting BE progression to EAC .…”

Section: Recent Advances In Diagnostic Surveillance In Be Dysplasiamentioning

confidence: 99%

Challenges to diagnostic standardization of Barrett's esophagus in Asia

Soh

Lee

Gotoda

et al. 2019

Digestive Endoscopy

View full text Add to dashboard Cite

Barrett's esophagus (BE), a premalignant condition of the lower esophagus, is increasingly prevalent in Asia. However, endoscopic and histopathological criteria vary widely between studies across Asia, making it challenging to assess comparability between geographical regions. Furthermore, guidelines from various societies worldwide provide differing viewpoints and definitions, leading to diagnostic challenges that affect prognostication of the condition. In this review, the authors discuss the controversies surrounding the diagnosis of BE, particularly in Asia. Differences between guidelines worldwide are summarized with further discussion regarding various classifications of BE used, different definitions of gastroesophageal junction used across geographical regions and the clinical implications of intestinal metaplasia in the setting of BE. Although many guidelines recommend the Seattle protocol as the preferred approach regarding dysplasia surveillance in BE, some limitations exist, leading to poor adherence. Newer technologies, such as acetic acid‐enhanced magnification endoscopy, narrow band imaging, Raman spectroscopy, molecular approaches and the use of artificial intelligence appear promising in addressing these problems, but further studies are required before implementation into routine clinical practice. The Asian Barrett's Consortium also outlines its ongoing plans to tackle the challenge of standardizing the diagnosis of BE in Asia.

show abstract

“…26 The mutational load score was compared between 23 patients with non-dysplastic Barrett’s esophagus or those with LGD who progressed to HGD/cancer and 46 patients with non-dysplastic Barrett’s esophagus or those with LGD who did not progress. The mutational load score was significantly higher in patients who progressed to HGD/cancer than in patients who did not.…”

Section: Use Of Biomarker Panels To Assess Cancer Risk In Barrett’s Ementioning

confidence: 99%

Beyond Dysplasia Grade

Dunbar

Souza

2017

Gastrointestinal Endoscopy Clinics of North America

View full text Add to dashboard Cite

SYNOPSIS Gastroenterology society guidelines recommend endoscopic surveillance as a means to detect early stage cancer in Barrett’s esophagus. However, the incidence of esophageal adenocarcinoma in Western countries continues to rise, suggesting that this strategy may be inadequate. Current surveillance methods rely on the endoscopist’s ability to identify suspicious areas of Barrett’s esophagus to biopsy, random biopsies, and on the histopathologic diagnosis of dysplasia. This review highlights the challenges of using dysplasia to stratify cancer risk, and addresses the development and use of molecular biomarkers and in vivo molecular imaging to detect early neoplasia in Barrett’s esophagus.

show abstract

The Presence of Genetic Mutations at Key Loci Predicts Progression to Esophageal Adenocarcinoma in Barrett’s Esophagus

Cited by 33 publications

References 50 publications

Overview of esophageal cancer

Overview of esophageal cancer

Challenges to diagnostic standardization of Barrett's esophagus in Asia

Beyond Dysplasia Grade

Contact Info

Product

Resources

About